Blueprint Medicines (NASDAQ:BPMC - Get Free Report)'s stock had its "outperform" rating reiterated by equities research analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They currently have a $128.00 target price on the biotechnology company's stock. Wedbush's target price suggests a potential upside of 32.55% from the company's current price.
Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. raised their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. JMP Securities reissued a "market outperform" rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Guggenheim reissued a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Stephens reissued an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Finally, Piper Sandler raised their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $123.83.
Read Our Latest Stock Analysis on Blueprint Medicines
NASDAQ BPMC traded up $6.15 during trading hours on Friday, hitting $96.57. 1,031,760 shares of the company's stock were exchanged, compared to its average volume of 995,940. The stock has a 50-day simple moving average of $99.54 and a 200 day simple moving average of $94.39. Blueprint Medicines has a 1-year low of $80.68 and a 1-year high of $121.90. The firm has a market cap of $6.17 billion, a price-to-earnings ratio of -89.42 and a beta of 0.62. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. On average, equities analysts forecast that Blueprint Medicines will post -1.28 EPS for the current fiscal year.
In other Blueprint Medicines news, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 1,819 shares of the business's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 45,224 shares of company stock worth $4,541,139. 4.21% of the stock is owned by company insiders.
Several hedge funds have recently made changes to their positions in the company. Torray Investment Partners LLC raised its stake in shares of Blueprint Medicines by 1.1% in the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after buying an additional 186 shares during the period. Sherbrooke Park Advisers LLC raised its stake in shares of Blueprint Medicines by 8.4% in the fourth quarter. Sherbrooke Park Advisers LLC now owns 3,374 shares of the biotechnology company's stock valued at $294,000 after buying an additional 261 shares during the period. Franklin Resources Inc. raised its stake in shares of Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after buying an additional 265 shares during the period. Summit Investment Advisors Inc. raised its stake in shares of Blueprint Medicines by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock valued at $580,000 after buying an additional 283 shares during the period. Finally, Pitcairn Co. raised its stake in shares of Blueprint Medicines by 2.8% in the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock valued at $925,000 after buying an additional 293 shares during the period.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.